To download the full report, click here.

The Pharmaceutical Research and Manufacturers of America (PhRMA) engaged Milliman to analyze the potential impact of moving all medications currently covered by Medicare Part B into the Medicare Part D benefit. Specifically, this report discusses the impact of this change to the Part D program. Our analysis focuses on the impact of this change alone - analyzing downstream changes to Part D, such as corresponding changes to Part D risk scores or member behaviors, was outside the scope of this analysis.